Abstract
Hepatocellular adenoma (HCA) is a rare, benign neoplasm of uncertain origin. It occurs predominantly in young adult women using long-term oral contraceptives. Spironolactone is a widely used diuretic agent. Despite the frequent use of spironolactone, there have been very few cases of hepatocellular toxicity reported. Furthermore, there are no reports to date in the English literature about HCA associated with spironolactone treatment for hyperaldosteronism. Herein, we present a HCA patient with hyperaldosteronism, who received spironolactone treatment for an extended period of time. The patient's HCA was enlarged and underwent hemorrhagic change. Therefore, eplerenone or surgical intervention may be superior to spironolactone in this patient.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
